ImmunityBio – 2026-01-16 - Increase Confidence 8/10

IBRX – Increase in Days/Weeks

ImmunityBio reported a staggering ~700% year-over-year revenue increase to $113 million in FY2025, driven by Anktiva adoption, just days after Saudi FDA approved the drug for NSCLC and NMIBC, expanding its global commercial footprint.

Why This Matters

The combination of explosive revenue growth and recent regulatory expansion signals a pivotal shift from a pre-revenue biotech to a commercial-stage growth story, which markets often revalue quickly—especially when paired with strong cash reserves and advancing clinical trials.

Key Insights

• Revenue Growth: Preliminary FY2025 revenue of $113M (~700% YoY), with Q4 alone at $38.3M (+431% YoY)
• News Impact: Saudi FDA approvals for ANKTIVA in NSCLC and NMIBC open new markets and validate clinical utility, boosting near-term sales potential
• Risk/Offset: Negative free cash flow (-$398M TTM) remains a concern, but $242.8M cash runway reduces near-term dilution risk

Practical Implications

• Bull Case: Continued sales momentum and trial enrollment progress could drive re-rating toward $6.50+ in 2–3 weeks
• Bear Case: High institutional ownership concentration may lead to volatility if sentiment shifts, but no immediate catalysts for decline
• Confidence: 8/10 – Strong revenue acceleration and regulatory tailwinds outweigh near-term financial risks

Prediction: increase

Reference:

• https://www.pharmiweb.com/press-release/2026-01-15/immunitybio-reports-continued-execution-and-sales-momentum-with-113-million-of-preliminary-net-prod
• https://www.insidermonkey.com/blog/is-immunitybio-inc-ibrx-the-best-us-stock-to-buy-under-20-1652253/
• https://finance.yahoo.com/quote/IBRX/